Neurent Medical is pioneering innovative treatments for chronic inflammatory sino-nasal diseases by targeting and disrupting hyperactive autonomic nerves that drive the underlying inflammation. NEUROMARK is a gentle in-office treatment for chronic rhinitis, a common condition characterized by persistent symptoms of nasal congestion, nasal drainage, and numerous other symptoms that severely impact patient quality of life.
Location: Ireland
Employees: 11-50
Total raised: $199.7M
Founded date: 2015
Investors 2
| Date | Name | Website |
| 01.03.2021 | Fountain H... | fh-partner... |
| 25.01.2021 | Life Scien... | lspvc.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 09.09.2026 | - | $29.11M | Claret Cap... |
| 10.07.2026 | Series C | $71.37M | - |
| 12.02.2026 | Series C | $74.22M | Momentum V... |
| 20.01.2021 | Series B | $25M | - |
Mentions in press and media 25
| Date | Title | Description |
| 14.09.2026 | European tech weekly recap: Over €3.9B invested across 70+ deals | Last week, we tracked more than 70 tech funding deals worth over €3.9 billion and over 5 exits, M&A transactions, rumours, and related news stories across Europe. 📊 The top three industries that raised the most were artificial intellige... |
| 09.09.2026 | Neurent Medical Secures €25 Million Growth Debt Facility from Claret Capital Partners to Accelerate Commercial Expansion | Neurent Medical, the pioneer behind the NEUROMARK® System for the treatment of chronic rhinitis, today announced that it has secured a €25 million growth debt financing facility from Claret Capital Partners. The financing will support the c... |
| 10.07.2026 | NEUROMARK® Treatment for Chronic Rhinitis Demonstrates Durable 2-Year Clinical Benefits | PARAGON Study Confirms Sustained Efficacy and Safety of NEUROMARK® System in Allergic and Nonallergic Rhinitis Patients Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal dise... |
| 10.07.2026 | Neurent Medical Announces 510(k) Clearance of its Next Generation NEUROMARK® System | Developed in Collaboration with Leading ENT Experts, the Enhanced NEUROMARK® System Reflects Meaningful Innovation and Delivers Real-Time Feedback to Improve Patient Care Neurent Medical, a leader in pioneering non-surgical solutions for ch... |
| 10.07.2026 | Neurent Medical Announces Publication of Positive Randomized Controlled Trial Results for the NEUROMARK® System | Study demonstrates superiority of radiofrequency posterior nasal nerve ablation versus sham control in patients with chronic rhinitis Neurent Medical, a leader in non-surgical treatments for chronic rhinitis, today announced the publication... |
| 10.07.2026 | Neurent Medical Raises €62.5 million in Oversubscribed Series C Financing | Neurent Medical, the pioneer behind NEUROMARK®, an innovative, minimally invasive solution to treat chronic rhinitis, today announced the successful close of its oversubscribed Series C financing, raising €62.5 million ($74 million) to driv... |
| 15.02.2026 | Neurent Medical Secures €62.5 Million to Propel NEUROMARK Expansion | Neurent Medical secured a substantial €62.5 million Series C funding round. This capital accelerates commercial growth for its NEUROMARK System. The innovative technology targets chronic rhinitis, offering durable relief. It employs impedan... |
| 12.02.2026 | Chronic rhinitis solution NEUROMARK secures €62.5 million as Irish startup Neurent Medical closes Series C | Galway-based Neurent Medical, the company behind NEUROMARK, a minimally invasive solution to treat chronic rhinitis, today announced the successful close of its oversubscribed Series C financing, raising €62.5 million ($74 million) to drive... |
| 12.02.2026 | Neurent Medical: €62.5 Million Series C Raised For Expanding NEUROMARK Commercially | Neurent Medical, a Galway, Ireland based medical technology company focused on chronic inflammatory sinonasal diseases, has closed an oversubscribed €62.5 million ($74 million) Series C financing to accelerate the commercial expansion of it... |
| 11.02.2026 | Neurent Medical Raises €62.5 million in Oversubscribed Series C Financing to Accelerate NEUROMARK® Commercial Expansion to treat Chronic Rhinitis | Neurent Medical, the pioneer behind NEUROMARK®, an innovative, minimally invasive solution to treat chronic rhinitis, today announced the successful close of its oversubscribed Series C financing, raising €62.5 million ($74 million) to driv... |
Show more